药捷安康-B：替恩戈替尼片新药上市申请获国家药品监督管理局受理

Core Viewpoint - The announcement indicates that the new drug application for Tienogratinib tablets has been accepted by the China National Medical Products Administration, targeting advanced, metastatic, or unresectable cholangiocarcinoma patients who have previously received at least one systemic therapy and FGFR inhibitor treatment [2] Group 1 - The drug Tienogratinib is intended for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma [2] - The application for Tienogratinib has been included in the priority review and breakthrough therapy lists prior to this acceptance [2]